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- This case report is the ﬁrst to describe the use of deep brain
stimulation in a patient with MECP2 duplication syndrome and
intractable seizures.
- We discuss the potential role of DBS in this population.
Chromosomal duplication at the Xq28 region including the
MECP2 gene (MECP2 duplication syndrome) is one of the most
common genomic rearrangements identiﬁed in neurodevelop-
mentally delayed males. The main clinical features include
infantile hypotonia, mild dysmorphic features, cognitive delay,
absent speech, recurrent infections, progressive spasticity and
autism. More than 50% of affected individuals develop epilepsy
with a high reported rate of drug resistant seizures. Up to 40% of
patients die before the age of 25 years with respiratory infections
being a frequent cause of death.1
Here we describe the long-term evolution of a 35 year-old
patient with MECP2 duplication syndrome who at the age of
20 years received deep brain stimulation (DBS) to the anterior
nucleus (AN) of the thalamus for the management of pharma-
coresistant seizures. Informed consent was obtained from the
patient’s caregiver to publish this report.* Corresponding author at: 5W-445, 399 Bathurst Street, Toronto, ON M5T 2S8,
Canada. Tel.: +1 416 603 5927; fax: +1 416 603 5768.
E-mail address: danielle.andrade@uhn.ca (D.M. Andrade).
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Developmental delay was ﬁrst observed at 9 months of age.
Independent walking was attained at 3 years. Speech was late and
he was never able to speak in full sentences. At 10-years-old, the
patient had some manual dexterity, was able to play soccer and
horseback ride. Speech and motor abilities were lost after the onset
of seizures at the age of 14. One year later he was not able to read,
count, or dress himself. It is not clear when the patient lost the
ability to walk as he was forced to use a wheelchair at all times due
to atonic seizures starting at the age of 15. Over his life he has had
multiple aspiration pneumonias, each time leading to ICU
admission and assisted ventilation. At 28-years-old a G-tube
was inserted due to recurrent aspiration pneumonias. Currently, at
35-years-old the patient is wheelchair bound with spastic
quadriparesis worse in the legs. He has severe cognitive delay,
does not talk nor does he respond to simple commands or make
eye contact. He shows frequent stereotypic movements charac-
terized by head bouncing down and to the side.
Seizure history: complex partial seizures (CPS) started at the age
of 14 years. Atonic seizures began one year later. He subsequently
developed secondarily generalized tonic clonic (2ly GTC) seizures,
atypical absence, tonic and eating-reﬂex seizures (head drop
associated with generalized epileptic discharges). His seizures
could not be controlled on different combinations of the follow-
ing drugs: valproate, phenytoin, clobazam, felbamate, carbamaz-
epine, lamotrigine, ethosuximide, vigabatrin, gabapentin and
topiramate.
Admission to the Epilepsy Monitoring Unit with continuous
video-EEG (expanded 10–20 international system with zygomatic
and subtemporal electrodes) revealed abnormally slow back-
ground activity. Interictal epileptiform discharges (IEDs): 2 Hz-
spike-and-slow-waves with generalized distribution and bilateral
synchrony, as well as multifocal independent spike foci (Fig. 1).
Atonic seizures (Fig. 2) and 2ly GTC seizures without clear onset
localization were recorded. MRI showed mild hyperintensity in the
white matter around the ventricular trigones.vier Ltd. All rights reserved.
Fig. 1. Interictal EEG showing generalized, frontally predominant slow spike and wave discharges. Bipolar anterior–posterior longitudinal montage. Time constant = 0.3;
HFF = 70 Hz.
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(DBS) to the anterior nucleus (AN) of the thalamus (patient AN3 in
Andrade et al.).2 The surgical procedure for the insertion of DBS
electrodes and implantable pulse generators has been previously
described.2 Electrode positioning was veriﬁed by postoperative
MRI. Activation and programming of the stimulators started one
month after the electrodes were implanted. The patient was
treated with carbamazepine and vigabatrin without dose changes
from 3 months prior until 2 years after the surgery.
The frequency of 2ly GTC seizures decreased from 125 per
month prior to AN DBS implantation to 60 per month one year
after active stimulation. After 4 years of treatment with AN DBS,
the frequency decreased further to 45.7 seizures per month. The
number of CPS decreased from 4–5 per day to 2–3 per week at 2
years follow up. The patient’s diagnosis was unclear until
microarray analysis was performed at age 35 and showed a
clinically signiﬁcant 0.641 Mb duplication in chromosome
region Xq28 that overlaps with the MECP2 duplication syndrome
region.
2. Discussion
Over 90% of patients with MECP2 duplication syndrome who
survive into adolescence have epilepsy.3 The seizure types
observed in MECP2 duplication syndrome are variable: GTC, tonic,
atonic, atypical absence, focal onset with or without 2ly GTC,
reﬂex, myoclonic and myoclonic-astatic. The EEG pattern can be
characterized by slowing or absence of the occipital dominant
rhythm as well as paroxysmal rhythmic slow theta activity in the
posterior regions. The epileptiform patterns found in these
patients are multifocal independent spike discharges and/orgeneralized spike and slow wave activity.1,3,4 Seizures resistant
to pharmacotherapy or ketogenic diet were reported in approxi-
mately 50% of all cases.1,4
Our patient is the oldest patient with well-described seizures
reported in the literature. His seizure types and interictal EEG are
in accordance with those described in the literature. Importantly,
this is the ﬁrst report on the use of DBS for seizure control in MECP2
duplication syndrome. When DBS electrodes were initially
implanted in our patient 15 years ago the diagnosis of MECP2
duplication was not known. The reduction in seizure frequency of
more than 50% after electrode implantation and stimulation was
statistically signiﬁcant. Importantly, this reduction enabled the
patient to have 1 or 2 day long periods of seizure freedom that did
not occur before DBS and were considered a signiﬁcant improve-
ment for him and his caregivers. The reduction in seizure
frequency has been maintained over the years (batteries were
recently replaced).
The majority of seizure reduction occurred within the ﬁrst
month of implantation before the electrodes were activated. This
suggests that the beneﬁcial effect of DBS in this patient may have
been related to the microthalamotomy caused by electrode
insertion. However, seizure frequency continued to decline over
the next years suggesting that the combination of microthala-
motomy and chronic stimulation were responsible for the long-
term beneﬁts observed following AN DBS. Although the number of
antiepileptic drugs was decreased after AN DBS the patient could
not be completely weaned and therefore AN DBS was not
sufﬁcient on its own in maintaining the improved level of seizure
control.
To the best of the authors’ knowledge, this is the only MECP2
duplication case to have received DBS. Therefore it is not known
Fig. 2. Atonic seizure; clinical onset in middle of ﬁgure marked by muscle and movement artifact, brief EEG attenuation followed by rhythmic frontally predominant delta
slow wave activity. Bipolar anterior–posterior longitudinal montage. Time constant = 0.3; HFF = 70 Hz.
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have a signiﬁcant response to DBS. Our patient experienced
improvements in the control of both generalized and partial
seizures with and without secondary generalization. However, AN
DBS might be preferentially effective for controlling certain types
of seizures (for instance, focal onset seizures may respond better to
AN DBS, whereas generalized onset seizures may respond better to
centro-median thalamic nuclei DBS) and may thus be more
effective for speciﬁc sub-groups of this patient population. Further
studies are needed to conﬁrm our observations.
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